Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI SWOT - About
PCVX 
Vaxcyte Inc (PCVX)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
10/20/2025: PCVX (3-star) is a STRONG-BUY. BUY since 15 days. Simulated Profits (19.10%). Updated daily EoD!
Upturn Star Rating
Moderate Performance
These Stocks/ETFs, based on Upturn Advisory, typically align with the market average, offering steady but unremarkable returns.
Number of Analysts
10 Analysts rated it
Moderately tracked stock, growing coverage, gaining market and investor attention.
1 Year Target Price $98
1 Year Target Price $98
| 9 | Strong Buy |
| 1 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit 53.41% | Avg. Invested days 41 | Today’s Advisory Strong Buy |
Upturn Star Rating | Upturn Advisory Performance  3.0 | Stock Returns Performance  3.0 |
| Profits based on simulation | Last Close 10/20/2025 |
Key Highlights
Company Size Mid-Cap Stock | Market Capitalization 5.50B USD | Price to earnings Ratio - | 1Y Target Price 98 |
Price to earnings Ratio - | 1Y Target Price 98 | ||
Volume (30-day avg) 10 | Beta 1.12 | 52 Weeks Range 27.66 - 116.00 | Updated Date 10/20/2025 |
52 Weeks Range 27.66 - 116.00 | Updated Date 10/20/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -4.11 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -16.44% | Return on Equity (TTM) -21.65% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 3634229236 | Price to Sales(TTM) - |
Enterprise Value 3634229236 | Price to Sales(TTM) - | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA -14.43 | Shares Outstanding 129823355 | Shares Floating 116843616 |
Shares Outstanding 129823355 | Shares Floating 116843616 | ||
Percent Insiders 0.65 | Percent Institutions 117.45 |
Upturn AI SWOT
Vaxcyte Inc
Company Overview
History and Background
Vaxcyte, Inc. (PCVX) is a clinical-stage vaccine innovation company revolutionizing the prevention of infectious diseases. Founded in 2013, it focuses on developing novel and improved vaccines to address current limitations in traditional vaccine approaches.
Core Business Areas
- Pneumococcal Conjugate Vaccine (PCV) Candidates: Vaxcyte's primary focus is on developing PCV candidates, with its lead candidate, VAX24, targeting the 24 most prevalent pneumococcal serotypes to provide broader coverage than existing vaccines.
Leadership and Structure
Grant Pickering serves as the CEO. The company has a typical biotech organizational structure with departments focused on R&D, clinical development, manufacturing, and commercialization.
Top Products and Market Share
Key Offerings
- VAX24: VAX24 is Vaxcyte's lead PCV candidate. It is designed to improve upon existing PCVs like Pfizer's Prevnar 20 by targeting more serotypes. Prevnar 20 generated significant revenue. Competitors include Pfizer (PFE) and Merck (MRK).
- VAX31: VAX31 is Vaxcyte's next-generation pneumococcal conjugate vaccine designed to cover 31 serotypes. Competitors include Pfizer (PFE) and Merck (MRK).
- Vaxcyte's pipeline: Vaxcyte has a pipeline of innovative vaccine candidates targeting other infectious diseases, including those caused by Group A Strep (GAS) and Meningitis. Competitors depend on the infectious diseases targeted
Market Dynamics
Industry Overview
The vaccine market is experiencing growth due to increasing awareness of preventative healthcare, rising infectious disease prevalence, and technological advancements in vaccine development.
Positioning
Vaxcyte aims to differentiate itself through broader serotype coverage and improved immunogenicity compared to existing PCVs. Its competitive advantage lies in its X-vivo platform for vaccine development.
Total Addressable Market (TAM)
The global pneumococcal vaccine market is substantial, projected to reach billions of dollars annually. Vaxcyte aims to capture a significant share of this market with its PCV candidates.
Upturn SWOT Analysis
Strengths
- Novel X-vivo platform technology
- Experienced leadership team
- Strong pipeline of vaccine candidates
- Potentially broader serotype coverage compared to existing vaccines
Weaknesses
- Clinical stage company with no currently marketed products
- High dependence on clinical trial success
- Significant R&D expenses
- Intense competition from established players
Opportunities
- Growing demand for pneumococcal vaccines
- Potential to capture market share from existing vaccines
- Expansion into new vaccine areas
- Partnerships and collaborations
Threats
- Clinical trial failures
- Regulatory hurdles
- Competition from established vaccine manufacturers
- Patent challenges
Competitors and Market Share
Key Competitors
- PFE
- MRK
Competitive Landscape
Vaxcyte faces strong competition from established players like Pfizer and Merck. Its competitive advantage relies on its next-generation vaccine candidates with broader coverage.
Growth Trajectory and Initiatives
Historical Growth: Vaxcyte's historical growth is characterized by the advancement of its vaccine candidates through preclinical and clinical stages.
Future Projections: Future growth is heavily dependent on successful clinical trial outcomes and regulatory approvals. Analyst estimates vary widely.
Recent Initiatives: Recent initiatives include the advancement of VAX24 into Phase 3 clinical trials and continued development of other pipeline candidates.
Summary
Vaxcyte is a clinical-stage company with innovative vaccine technology, particularly in pneumococcal vaccines. Success hinges on clinical trial results and regulatory approvals, facing competition from established pharmaceutical giants. Recent progress in clinical trials positions the company for potential future growth, but failure to obtain regulatory approval would be a major set back. They need to keep a close eye on cash burn to ensure enough runway.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company filings
- Analyst reports
- Industry publications
Disclaimers:
This analysis is for informational purposes only and should not be considered investment advice. The data provided is based on publicly available information and may be subject to change.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Vaxcyte Inc
Exchange NASDAQ | Headquaters San Carlos, CA, United States | ||
IPO Launch date 2020-06-12 | Co-Founder, CEO & Director Mr. Grant E. Pickering M.B.A. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 414 | Website https://vaxcyte.com |
Full time employees 414 | Website https://vaxcyte.com | ||
Vaxcyte, Inc., a clinical-stage vaccine innovation company, develops conjugate and novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent carrier-sparing investigational pneumococcal conjugate vaccine (PCV) for the prevention of invasive pneumococcal disease (IPD) in infants. The company also develops VAX-31, a 31-valent, carrier-sparing investigational PCV for the prevention of IPD in adults and children; VAX-A1, a novel conjugate vaccine candidate to prevent disease caused by Group A Streptococcus; VAX-PG, a novel protein vaccine candidate targeting the keystone pathogen responsible for periodontitis; and VAX-GI, a novel preclinical vaccine candidate for the treatment of dysentery and shigellosis, which is caused by Shigella bacteria. The company was formerly known as SutroVax, Inc. and changed its name to Vaxcyte, Inc. in May 2020. Vaxcyte, Inc. was incorporated in 2013 and is headquartered in San Carlos, California.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.